Positive topline results from Phase 3 trial in Rett syndrome
Filed with ASX · · 5 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Neuren presenting at Bell Potter Healthcare Conference
- Q3 2021 quarterly activity and cash flow report
- Neuren receives feedback on IND for Phelan-McDermid syndrome
- US patent to 2034 granted for Neurens NNZ-2591 in autism
- $3.3 million raised from oversubscribed SPP
Later from Neuren Pharmaceuticals
- Q4 2021 quarterly activity and cash flow report
- Notification regarding unquoted securities - NEU
- Preliminary Final Report and 2021 Full Year Accounts
- 2021 Results - a transformational year for Neuren
- FDA approval for Angelman IND and Phase 2 trial
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals